Lillyroulettecasinogame.US) fell 3% to $733.27. on the news frontroulettecasinogameAmgen's mid-term trial of a new weight-loss drug has received positive data, and if the drug is approved, it will compete with Novo Nordisk's Wegovy and Lilly's Zepbound.

Earlier, some media said that Amgen is trying a new weight-loss drug, whose mechanism of action is different from Novo Nordisk and Lilly products, which can prevent patients from gaining weight even if they stop taking the drug.